Depemokimab - GSK
Alternative Names: AQ82742999; GSK 294; GSK-3511294Latest Information Update: 23 Jul 2024
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Interleukin 5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Asthma; Churg-Strauss syndrome; Hypereosinophilic syndrome; Rhinosinusitis
Most Recent Events
- 11 Apr 2024 GlaxoSmithKline completes the phase III SWIFT-2 trial in Asthma (In adolescents, In adults, In children, In the elderly, Adjunctive treatment) in USA, Australia, Canada, Czech Republic, France, Hungary, Italy, Japan, Poland, Spain, Taiwan (Injection), after February 2021 (NCT04718103)
- 21 Nov 2023 GlaxoSmithKline completes a phase III SWIFT 1 trial in Asthma (In adolescents, In adults, In children, In the elderly, Adjunctive treatment) the US, Canada, China, Czechia, France, Germany, Ireland, Italy, Poland, Russia, Spain and the United Kingdom (NCT04719832) (EudraCT2020-003632-25; 206713)
- 23 Oct 2023 GlaxoSmithKline completes a phase I pharmacokinetics trial for Asthma (In volunteers) (SC, Injection) (NCT05602025)